Clofibrate in Ischemic Heart Disease
Authors: WILLIAM T. FRIEDEWALD
Journal: Annals of Internal Medicine (1972)

Editorials1 May 1972Clofibrate in Ischemic Heart DiseaseWILLIAM T. FRIEDEWALD, M.D., MAX HALPERIN, PH.D.WILLIAM T. FRIEDEWALD, M.D., MAX HALPERIN, PH.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-76-5-821 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe efficacy of clofibrate treatment for primary and secondary prevention of ischemic heart disease has been a topic of keen interest for some time, mainly because of the lipid-lowering properties of this drug, and its relatively low incidence of adverse effects. A recent issue of theBritish Medical Journalcontains reports from two completed secondary-prevention trials of clofibrate, one by a group of physicians in the Newcastle-upon-Tyne region (1, 2) and one by a research committee of the Scottish Society of Physicians (2, 3). These trials were separate, cooperative ventures and used a randomized, double-blind design, except for a subsegment...References1. : Trial of Clofibrate in the treatment of ischemic heart disease. Br Med J 4:767-775, 1971 CrossrefMedlineGoogle Scholar2. DEWAROLIVER HM: Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials. Ibid., pp. 784-786 Google Scholar3. : Ischemic heart disease: a secondary prevention trial using clofibrate. Ibid., pp. 775-784 Google Scholar4. ZELEN M: The analysis of several 2x2 contingency tables. Biometrika 58:129-137, 1971 Google Scholar5. : Control of hyperlipidemia. IV. Progress in drug trials of secondary prevention, with particular reference to the coronary drug project, in Atherosclerosis: Second International Symposium 1970, edited by JONES RJ. New York, Springer-Verlag, 1970, pp. 586-594 Google Scholar6. : Unpublished observations Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: WILLIAM T. FRIEDEWALD, M.D.; MAX HALPERIN, PH.D.Affiliations: Biometrics Research Branch National Heart and Lung Institute National Institutes of Health Bethesda, Md. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byImpaired Vascular Function in Physically Active Premenopausal Women With Functional Hypothalamic Amenorrhea Is Associated With Low Shear Stress and Increased Vascular ToneSerum Retinol and Carotenoids in Association with Biomarkers of Insulin Resistance among Premenopausal WomenExercise as an alternative to oral estrogen for amelioration of endothelial dysfunction in postmenopausal womenHemodynamic after-effects of acute dynamic exercise in sedentary normotensive postmenopausal womenPrimary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol.Antiplatelet Agents: Rationale and ResultsCholesterol, colestipol and coronary heart diseaseColestipol hydrochloride in hypercholesterolemic patients—Effect on serum cholesterol and mortalityAntiplatelet drugs — A new pharmacologic approach to the prevention of thrombosisPlatelet-Inhibiting Drugs in the Prevention of Clinical Thrombotic DiseaseEffects of clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease.The Rationale for Hypolipemic TherapyChapter 19. Atherosclerosis 1 May 1972Volume 76, Issue 5Page: 821-823KeywordsCardiovascular therapyDrugs ePublished: 1 December 2008 Issue Published: 1 May 1972 PDF downloadLoading ...